HanchorBio and Henlius ink deal worth up to $202 million

2 July 2025

Taiwanese biotech HanchorBio (TWO: 7827O) has signed a licensing agreement with China’s Shanghai Henlius Biotech (HKG: 2696).

The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China—including the Chinese mainland, Hong Kong and Macau—along with key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology